Clinical Operations & Patient Safety · Healthcare & Life Sciences
Should you build or buy Medication Safety & Adverse Drug Event Surveillance?
Medication safety and adverse drug event surveillance software monitors prescription orders, dispensing records, lab values, and clinical notes to detect potential medication errors, high-risk drug exposures, and adverse drug events before or after they reach the patient. It applies clinical pharmacology rules — Beers criteria, renal dosing adjustments, drug interaction databases — to flag outliers and route alerts to pharmacists or clinical safety teams.
The build-vs-buy decision for Medication Safety & Adverse Drug Event Surveillance turns on how readily your team can encode and maintain clinical pharmacology rules against your EHR's owned data, and how far AI-assisted rules engines have shifted the cost equation relative to what vendors charge; the specifics decide it — and the gap is narrowing.
Build it, buy it, or bridge?
When building makes sense
Medication safety surveillance is one of the cleaner ML problems in healthcare, which is why large IDNs and academic health systems have been running homegrown ADE surveillance for years. The data is owned — it lives in your EHR — and the clinical rules are well-documented: Beers criteria, renal dosing adjustment protocols, drug interaction databases. Open-source anomaly detection tooling has made the model layer increasingly accessible, and LLM-assisted clinical rules generation is starting to make building a custom rules engine cheaper than it was even two years ago. The build case gets serious when you want detection models tuned to your specific formulary and patient population — your actual drug mix, your patient's renal function distribution, your high-risk medication set — rather than vendor defaults calibrated across a different institution mix. Clinical informatics teams at large IDNs often find that generic vendor models have either too many false positives (for their population) or miss patterns specific to their formulary. Custom surveillance fixes that, and the maintenance burden of staying current with drug interaction databases is real whether you build or buy.
When buying makes sense
Buying earns its keep when you need the full detection-to-reporting workflow — including cross-system integration, alert management dashboards, and pharmacist workflow routing — without an internal clinical informatics team to build and own it. Vendors like MedAware, Bainbridge Health, and the VigiLanz pharmacy module package the detection logic with the downstream workflow that most pharmacy safety teams expect out of the box: alert triage views, case documentation, and reporting. For hospitals without dedicated clinical pharmacology informatics staff, there is no realistic path to building custom surveillance rules at the depth vendors provide. The drug interaction database maintenance argument is also persuasive: FDA drug safety communications, new black box warnings, and updated Beers criteria all require rule updates, and vendors absorb that refresh cycle as part of their platform. Even for organizations considering building their own detection models, using a vendor platform for alert management and cross-system reporting while running internal models alongside it is a defensible architecture.
The desk read
Anomaly detection on structured pharmacy and lab data is one of the cleaner ML problems in healthcare, which is why large IDNs and academic health systems have been running homegrown ADE surveillance for years. The data is owned (it lives in your EHR), the clinical rules are well-documented (Beers criteria, renal dosing adjustments, drug interaction databases), and open-source tooling makes the model layer increasingly accessible. The build case gets serious when you want models tuned to your specific formulary and patient mix rather than vendor defaults.
Buying earns its keep when you need the full detection-to-reporting workflow, including cross-system integration and alerting dashboards, without an internal clinical informatics team to own the build. Vendors like MedAware and Bainbridge Health package the detection logic with the alert management and reporting layer that most pharmacy teams expect out of the box. LLMs are starting to assist with clinical rules engine generation, making the build path cheaper than it was two years ago, but the maintenance burden of staying current with drug interaction databases is ongoing either way.
Frequently asked
What is Medication Safety & Adverse Drug Event Surveillance software?
Medication safety and adverse drug event surveillance software monitors prescription orders, dispensing records, lab values, and clinical notes to detect potential medication errors, high-risk drug exposures, and adverse drug events before or after they reach the patient. It applies clinical pharmacology rules — Beers criteria, renal dosing adjustments, drug interaction databases — to flag outliers and route alerts to pharmacists or clinical safety teams.
When does building Medication Safety & Adverse Drug Event Surveillance make sense?
Building is tractable for large IDNs with clinical informatics teams — the data is owned and the clinical rules are documented. The case strengthens when you need detection tuned to your specific formulary and patient mix rather than vendor defaults, and LLM-assisted rules engine generation is making the build path cheaper than it used to be.
When does buying Medication Safety & Adverse Drug Event Surveillance make sense?
Buying makes sense when you need the full detection-to-reporting workflow without internal clinical pharmacology informatics staff. Vendors package alert management, cross-system integration, and ongoing drug database maintenance that would otherwise require a continuous internal commitment.
What are the main Medication Safety & Adverse Drug Event Surveillance vendors?
Representative vendors include MedAware, Health Catalyst Patient Safety Monitor, VigiLanz (Pharmacy/ADE module), Bainbridge Health. B4 Pro scores the full set.
How is ADE surveillance different from the drug interaction checking built into most EHRs?
EHR-embedded drug interaction checking is point-of-prescribing — it fires at order entry. ADE surveillance runs continuously across all active medications, lab trends, and clinical notes, catching exposures that slip through at ordering (dose accumulation, renal function changes after the initial order, population-level outlier patterns). Dedicated surveillance platforms are also designed to minimize alert fatigue by applying smarter thresholds than EHR default checks, which are typically calibrated too broadly.